This classical model of lupus nephritis is responsive to treatments targeting IL-6 [7], Bruton’s tyrosine kinase (BTK) inhibitor [8,9], CD20 [10], BAFF [11], glucocorticoid receptor [12], and CTLA-4 [13]. This evidence concerns the gene BTK and lupus nephritis.